Search results for "SKIN"
showing 10 items of 3630 documents
Risk Factors for Secondary Cancer in a Case-Control Study on 1,259 Patients with Myeloproliferative Neoplasms
2018
Abstract INTRODUCTION The incidence of secondary cancer (SC) in patients with myeloproliferative neoplasms (MPN) is high and comparable to that of thrombosis. However, the identification of patient subgroups that might be at increased susceptibility of developing SC has not been systematically addressed. We report here the results of an international case-control study (MPN-K) aimed at comparing the frequency of exposure to possible causes of SC in patients with classical MPN, polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF). METHODS This European Leukaemia Network (ELN) study reports MPN patients from 28 sites of 5 European countries and Israel, diagnosed in th…
Congenital myopathy and epidermolysis bullosa due to PLEC variant
2021
Abstract We report on an adult Turkish patient with mild myopathy with a fiber-type disproportion and mitochondrial disorganization caused by genetic variants in the plectin gene (PLEC). Molecular genetic panel testing revealed two homozygous variants in PLEC (NM_000445.4): c.8306C>G (p.Pro2769Arg) and c.7506 + 5C>G (p. ?) that were classified as variants of unknown significance (class 3) following ACMG guidelines for variant classification in genetic diagnostics. A thorough reassessment of the patient revealed mild skin blistering (epidermolysis bullosa simplex, EBS). This illustrates the importance of deep phenotyping of neuromuscular patients.
Norwegian (crusted) scabies of glans penis in an immunocompetent patient
2009
Limitations of nasal nitric oxide as a screening method of primary ciliary dyskinesia in childhood
2016
Introduction: Nasal nitric oxide (nNO) has been proposed as a screening tool for primary ciliary dyskinesia (PCD). However, there are no reference values by age in consensus guidelines. Objectives: 1) To analyze differences in nNO among a group of patients with PCD and healthy controls. 2) To determine the proportion of pediatric PCD patients with nNO values similar to healthy population. Methods: Determination of nNO by electrochemical system (NIOX Vario®) in patients with DCP (diagnosis confirmed by digital high speed videomicroscopy) and healthy controls (without asthma, rhinitis or atopic dermatitis), aged between 7 and 60 years. Results: 32 patients (17 children, 53.1%) and 32 controls…
Cutaneous Adverse Reactions to Highly Antiretroviral Therapy in HIV-Positive Patients
2013
Adverse drug reactions to highly antiretroviral therapy (HAART) are major obstacles in its success. Although overall mortality from HIV has dramatically declined owing to HAART, these antiretroviral regimens have been associated with a wide spectrum of severe cutaneous reactions. The severity of cutaneous adverse reactions varies greatly, and some may be difficult to manage. To optimize adherence and efficacy of antiretroviral treatment, clinicians must focus on preventing adverse effects whenever possible, and distinguish those that are self-limited from those that are potentially serious. This paper presents the case of a serious cutaneous adverse reaction to Atripla in a HIV-positive 50-…
Epigastric cutaneous discharge: think amoebiasis
2020
Responsiveness and minimal important difference of the urticaria control test
2017
This study demonstrates the responsiveness of the Urticaria Control Test (UCT). Changes of its score by 3 points or more reflect a clinically relevant change of disease control (minimal important difference).
FRI0318 Health care resource utilisation (HCRU) and cost analyses of systemic lupus erythematosus (SLE) as a function of disease severity: analysis o…
2018
Background SLE is a severe, chronic autoimmune disease of the connective tissue involving multiple organ systems. Understanding the economic burden of SLE in the context of disease severity is important when considering new therapeutic options. Objectives HCRU and costs associated with SLE were examined retrospectively using anonymized data from a German Sickness Fund database. Methods Real-world claims for adult (≥18 years old) patients (pts) with SLE from a German Sickness Fund database of company health insurance schemes were analysed. HCRU and costs were assessed annually for 2009–2014 for pts diagnosed with SLE in 2009 and validated using repeated SLE-related claims, co-diagnosis codes…
PS8:160 Health care resource use (hru) and medical cost analyses as a function of systemic lupus erythematosus (sle) disease severity: analysis of cl…
2018
Purpose Real-world HRU and medical cost analyses support drug development in SLE. The economic burden of SLE as a function of disease severity was quantified for a German cohort. Methods HRU and cost analyses were performed for patients (≥18 years old) with SLE and compared with those of matched controls for 2009–2014 using the Betriebskrankenkassen (BKK) German Sickness Fund Database. BKK is a branch of the statutory German health insurance. SLE was confirmed in 2009 using the diagnosing physician’s specialty, repeated SLE-related claims, co-diagnosis codes, laboratory tests, or prescriptions. At least 3 years’ data was also required prior to 2009. SLE cases were control matched by age, se…
Treatment of Non-Melanoma Skin Cancer with Different Radiation Techniques
2014
ABSTRACT Aim: To compare local control and toxicity in non melanoma skin cancer treated with electrons and Leipzig applicators. Methods: We evaluated 60 patients (pts) with non melanoma skin cancer treated using electrons and Leipzig applicators (microselectron-HDR afterloader). The lesions were: 30 basal cell cancer, 17 squamous cell cancer, 10 basosquamous cell cancer, 1 dermatofibrosarcoma, 1 keloid, 1 histiocytoma fibrosus. Median age was 54 (25-84). The lesions were localized on head and neck, except 1 in the sternum and 1 in posterior part of knee. 49 pts underwent surgery before radiation treatment with negative margin in 38 pts and positive margins in 11. 30 pts were treated with el…